Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-05-04T03:05:18.718Z Has data issue: false hasContentIssue false
  • English
  • Français

Zuclopenthixol, D1/D2 antagonist, for treatment of chronic aggressive schizophrenia and psychotic oligophrenic patients

Published online by Cambridge University Press:  16 April 2020

A Grinshpoon ,
M Moskowitz ,
A Valevski ,
A Kreizman ,
L Palei ,
M Mar  and
A Weizman
A Grinshpoon
Affiliation:
Mental Health Service, Israel Ministry of Health and Israel Defence Forces
M Moskowitz
Affiliation:
Naveh-Yaakov Psychiatric Hospital, Petah Tiqva
A Valevski
Affiliation:
Gehah Psychiatric Hospital, Rabin Medical Center, Beilinson Campus, PO Box 102, Petah Tiqva 49 100; and
A Kreizman
Affiliation:
Naveh-Yaakov Psychiatric Hospital, Petah Tiqva
L Palei
Affiliation:
Naveh-Yaakov Psychiatric Hospital, Petah Tiqva
M Mar
Affiliation:
Mental Health Service, Israel Ministry of Health and Israel Defence Forces
A Weizman*
Affiliation:
Gehah Psychiatric Hospital, Rabin Medical Center, Beilinson Campus, PO Box 102, Petah Tiqva 49 100; and Felsenstein Medical Research Center, Beilinson Campus, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
*
*Correspondence and reprints.
Get access

Summary

An open label trial was conducted to study the efficacy of zuclopenthixol decanoate, a D1/D2 antagonist, in the treatment of chronic (> 10 years) neuroleptic-resistant aggressive schizophrenia (n = 10) and psychotic oligophrenic patients (n = 6). A significant reduction was noted in the Brief Psychiatric Rating Scale score, especially in the clusters of hostility-suspiciousness and excitement. After many years of seclusion, ten of the 16 patients were transferred to an open psychiatric department and were allowed to visit their families.

Keywords

schizophreniamental retardationzuclopenthixolaggressiondopamine D1 and D2 receptors
Type
Case report
Information
European Psychiatry , Volume 13 , Issue 5 , August 1998 , pp. 273 - 275
Copyright
Copyright © Elsevier, Paris 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Christensen, AV, Arnt, V, Hyttel, V, Svendsen, OBehavioral correlates to dopamine D1 and D2 antagonists Pol J Pharmacol Pharm 36 1985 249–264Google Scholar
Cohen, SA, Underwood, MTThe use of clozapine in mental retarded and aggressive population J Clin Psychiatry 55 1994 440–444Google ScholarPubMed
Karsten, D, Vidimaeki, T, Linna, SL, Pollari, L, Turunen, SNeuro-Ieptic treatment of oligophrenic patients Acta Psychiatrica Scand 64 1981 39–45Google Scholar
Kazi, HAGAn open clinical trial with the long-acting neuro-leptic zuclopenthixol decanoate in the maintenance treatment of schizophrenia Pharmatherapeutica 4 1986 555–560Google ScholarPubMed
Lublin, H, Gerlach, J, Hagert, U, Meidahl, B, Molbjerg, C, Pedersen, Vet alZuclopenthixol, a combined dopamine D1 D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia Eur Neuropsychopharmacol 1 1991 541–548CrossRefGoogle ScholarPubMed
Malt, UF, Nystad, R, Bache, T, Noren, O, Sjaastad, M, Solberg, KOet alEffectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioral disturbances in learning disabled patients Br J Psychiatry 166 1995 374–377CrossRefGoogle Scholar
Overall, JE, Gorham, DRThe Brief Psychiatric Rating Scale Psychol Rep 10 1962 799–812CrossRefGoogle Scholar
Ratey, JJ, Leveroni, C, Kilmer, D, Gutheil, C, Swartz, BThe effects of clozapine on severely aggressive psychiatric inpatients in a state hospital J Clin Psychiatry 54 1993 219–223Google ScholarPubMed
Walker, CAA doubleblind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic outpatients Pharmatherapeutica 3 1983 289–293Google Scholar
Wistedt, B, Koskinen, T, Thelander, S, Nerdrum, T, Pedersen, V, Mølbjerg, CZuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicenter study Acta Psychiatr Scand 84 1991 14–21CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.